A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

A Multi-center Observational Study of the Effectiveness of Elranatamab in Patients With Relapsed and/or Refractory Multiple Myeloma in Taiwan

The purpose of this study is to evaluate:

• What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan?
• What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan?
• What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?

This study is seeking participants who:

• have relapsed or refractory multiple myeloma (RRMM),
• have received at least four prior lines of therapy (including a PI, an IMiD, and an anti-CD38 antibody),
• are 18 years or older.

Participants receive elranatamab according to the approved label in Taiwan and continue treatment until disease progression or discontinuation. The study will evaluate real-world effectiveness and describe patient characteristics and treatment patterns to better understand elranatamab use in routine care.

Inclusion criteria:

1. Patients age ≥ 18 years at the initiation of elranatamab
2. Patients who have received at least one dose of elranatamab in consistent with the approved label in Taiwan.
3. Evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. The ICD waiver is acceptable for patient who was ceased before recruitment.

Exclusion criteria:

Patients who participated in any prior clinical trials using elranatamab.